S2324 Mycophenolate Mofetil vs Azathioprine for Maintenance Therapy in Autoimmune Hepatitis: A Retrospective Matched Cohort Study

Introduction: Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disorder that requires long-term immunosuppressive therapy to prevent disease progression and relapse. While azathioprine (AZA) remains the standard maintenance treatment following corticosteroid induction, mycophenolate mofetil (MMF) is increasingly used in patients who are intolerant or unresponsive to AZA. This study aims to compare the clinical and biochemical outcomes of MMF versus AZA in the maintenance treatment of AIH. Methods: A retrospective cohort analysis was conducted on adult patients with AIH who achieved disease remission following corticosteroid induction and were subsequently treated with either MMF or AZA. Patients were matched for baseline characteristics, including liver enzyme levels and immunoglobulin G (IgG) values. Biochemical response was assessed through changes in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Tolerability and adverse events were also recorded. Results: A total of 52 patients were included, with matched cohorts for MMF and AZA. After induction, patients treated with MMF experienced a greater reduction in alanine aminotransferase (−27.1 U/L vs −20.3 U/L) and AST (−31.4 U/L vs −23.6 U/L) compared to those on AZA. The rate of biochemical normalization was higher in the MMF group, and MMF was generally well tolerated with no significant increase in adverse events. No patients required escalation to second-line therapy during the follow-up period. Conclusion: In this matched analysis of AIH patients, MMF was associated with greater improvements in liver enzyme levels compared to AZA, suggesting superior biochemical response. MMF may be a more effective and well-tolerated maintenance option in selected AIH patients, particularly those unable to tolerate or respond adequately to AZA. Further prospective studies are warranted to validate these findings.

Authors

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001136756.89918.08
Primary Topic
Liver Diseases and Immunity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S2324 Mycophenolate Mofetil vs Azathioprine for Maintenance Therapy in Autoimmune Hepatitis: A Retrospective Matched Cohort Study

Shahem Abbarh, Mohammed Abu‐Rumaileh, Fayaz Khan, Sami Ghazaleh et al.
The American Journal of Gastroenterology
Liver Diseases and Immunity
article

S2324 Mycophenolate Mofetil vs Azathioprine for Maintenance Therapy in Autoimmune Hepatitis: A Retrospective Matched Cohort Study

Shahem Abbarh, Mohammed Abu‐Rumaileh, Fayaz Khan, Sami Ghazaleh, Mhd Kutaiba Albuni, Bisher Sawaf, Yusuf O. Hallak, Maram Albandak, Sana Rabeeah
article en

Abstract

Introduction: Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disorder that requires long-term immunosuppressive therapy to prevent disease progression and relapse. While azathioprine (AZA) remains the standard maintenance treatment following corticosteroid induction, mycophenolate mofetil (MMF) is increasingly used in patients who are intolerant or unresponsive to AZA. This study aims to compare the clinical and biochemical outcomes of MMF versus AZA in the maintenance treatment of AIH. Methods: A retrospective cohort analysis was conducted on adult patients with AIH who achieved disease remission following corticosteroid induction and were subsequently treated with either MMF or AZA. Patients were matched for baseline characteristics, including liver enzyme levels and immunoglobulin G (IgG) values. Biochemical response was assessed through changes in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Tolerability and adverse events were also recorded. Results: A total of 52 patients were included, with matched cohorts for MMF and AZA. After induction, patients treated with MMF experienced a greater reduction in alanine aminotransferase (−27.1 U/L vs −20.3 U/L) and AST (−31.4 U/L vs −23.6 U/L) compared to those on AZA. The rate of biochemical normalization was higher in the MMF group, and MMF was generally well tolerated with no significant increase in adverse events. No patients required escalation to second-line therapy during the follow-up period. Conclusion: In this matched analysis of AIH patients, MMF was associated with greater improvements in liver enzyme levels compared to AZA, suggesting superior biochemical response. MMF may be a more effective and well-tolerated maintenance option in selected AIH patients, particularly those unable to tolerate or respond adequately to AZA. Further prospective studies are warranted to validate these findings.

The American Journal of GastroenterologyVol. 120(10S2)
Openalex Percentile: Top 48%
Liver Diseases and Immunity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.